Benign melanocyticAcralICD-10 D22.7

Acral melanocytic naevi

Acral lentiginous naevus (benign); palmoplantar naevus; volar naevus

Acral melanocytic naevi are benign pigmented lesions on palms, soles and digits. They are far more conspicuous in Fitzpatrick IV–VI skin, where they make up a substantial proportion of all naevi, and remain the principal benign differential for acral lentiginous melanoma. Three benign dermoscopic patterns predominate — parallel-furrow, lattice-like and fibrillar — all of which reflect pigment in the narrower furrows of the dermatoglyphics rather than the wider ridges. The parallel-ridge pattern of acral lentiginous melanoma reverses this distribution and is the single most useful early warning sign on dermoscopy.

CurrentLast reviewed 15 May 2026
Clinical image of Acral melanocytic naevi
Acral melanocytic naevi. Image sourced from DermNet New Zealand. Used under CC BY-NC-ND 4.0. No endorsement implied.

Clinical features

  • Well-circumscribed, evenly pigmented brown macule or thin papule on palms, soles, fingers or toes.
  • Usually 2–8 mm; larger lesions warrant closer scrutiny.
  • Common from childhood; persistence into adulthood is normal.
  • Proportionally commoner in Fitzpatrick IV–VI skin.
  • Subungual / nail-matrix naevi present as longitudinal melanonychia, typically < 3 mm wide with uniform colour — see subungual melanoma for melanoma red flags.

Benign dermoscopic patterns

  • Parallel-furrow pattern — pigment along the narrower furrows of the dermatoglyphics; commonest benign pattern, particularly on the sole.
  • Lattice-like pattern — pigment crossing the furrows with additional perpendicular lines; common on the arch.
  • Fibrillar pattern — fine oblique pigmented lines crossing the surface; common on weight-bearing areas.
  • Less common but benign — globular, reticular, homogeneous patterns (mostly in children and on the dorsum / less acral areas).

Parallel-ridge — the melanoma warning

  • The parallel-ridge pattern — pigment deposited along the wider ridges rather than the narrower furrows — is the classical dermoscopic finding of acral lentiginous melanoma.
  • High-specificity sign in trained hands; the original Saida series reported sensitivity in the mid-80% range and specificity ~99% for early acral melanoma, but performance depends on training and lesion mix.
  • Any acral lesion with parallel-ridge pattern, multicomponent pattern, asymmetric pigmentation, blue-white veil or peripheral pigment must be referred urgently.
  • The CASH (Colour, Architecture, Symmetry, Homogeneity) approach helps risk-stratify uncertain acral lesions.

Special situations

  • Acral naevi in skin of colour — a major equity issue. ALM is over-represented in Fitzpatrick IV–VI and frequently presents late; threshold for biopsy should be lower in this population.
  • Subungual naevus vs subungual melanoma — Hutchinson sign (pigment extending onto the nail fold) is concerning but not pathognomonic (pseudo-Hutchinson exists in benign disease).
  • Children and adolescents — congenital and acquired acral naevi are common; the parallel-ridge pattern is seen far less reliably as a melanoma marker in this group, and benign acral naevi may show transient atypical patterns.

Management and biopsy

  • Routine review for stable, symmetrical lesions with benign dermoscopic patterns.
  • Biopsy and refer if asymmetry, parallel-ridge, multicomponent or evolving features.
  • Excisional biopsy preferred over shave for acral pigmented lesions where melanoma is possible — preserves depth.
  • Nail-matrix biopsy for atypical longitudinal melanonychia > 3 mm wide, asymmetric, or with Hutchinson sign.

References

  1. Saida T et al. Significance of dermoscopic patterns in detecting early acral lentiginous melanoma. J Am Acad Dermatol; 2004.
  2. Phan A et al. Acral lentiginous melanoma — clinicoprognostic features in a cohort. Br J Dermatol; 2010.
  3. Bristow IR, de Berker DA. Acral lentiginous melanoma — clinical update. Br J Dermatol; 2018.
  4. NICE NG14. Melanoma: assessment and management. London: NICE; 2015 (last updated 27 July 2022).

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.